Bafna Pharmaceuticals (NSE:BAFNAPH) 6-Month Price Index: 2.94 (As of Sep. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BAFNAPH Bafna Pharmaceuticals Ltd NSE:BAFNAPH
57 GF Score
Price ₹312.60
GF Value ₹85.61
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Bafna Pharmaceuticals 6-Month Price Index?

Bafna Pharmaceuticals NSE:BAFNAPH +2.74% 57 6-Month Price Index is 2.94 as of Sep. 01, 2026. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 57/100 and a GF Value™ of ₹85.61 (Significantly Overvalued). The stock has 9 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-09-01), Bafna Pharmaceuticals's 6-Month Price Index is 2.94.

Bafna Pharmaceuticals  (NSE:BAFNAPH) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Bafna Pharmaceuticals 6-Month Price Index Related Terms

NSE:BAFNAPH vs ZTS: 6-Month Price Index Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NSE:BAFNAPH
57GF Score
Bafna Pharmaceuticals Ltd NSE:BAFNAPH
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bafna Pharmaceuticals  (NSE:BAFNAPH) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 2.94 mean?
Bafna Pharmaceuticals (NSE:BAFNAPH) has a 6-Month Price Index of 2.94 as of Sep. 01, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Bafna Pharmaceuticals and its competitors.
Is Bafna Pharmaceuticals' 6-Month Price Index too high?
Bafna Pharmaceuticals' current 6-Month Price Index is 2.94. Overall, Bafna Pharmaceuticals has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' 6-Month Price Index compare to ZTS?
Bafna Pharmaceuticals' 6-Month Price Index of 2.94 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Drug Manufacturers company?
A good 6-Month Price Index depends on the Drug Manufacturers industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Bafna Pharmaceuticals and its competitors. Bafna Pharmaceuticals's current 6-Month Price Index is 2.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹85.61, compared to a current price of ₹312.60 — trading 265.1% above its estimated fair value. The current 6-Month Price Index is 2.94. Bafna Pharmaceuticals' overall GF Score™ is 57/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current 6-Month Price Index is 2.94 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?

Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued. The current stock price of ₹312.60 is trading 265.1% above its estimated GF Value™ of ₹85.61. GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NSE:BAFNAPH:

  • 6-Month Price Index: 2.94
  • GF Value™: ₹85.61 vs. price of ₹312.60 (265.1% above fair value)
  • GF Score™: 57/100 with 9 warning signs

No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bafna Pharmaceuticals Business Description

Other Exchanges 532989:India
Address Thambu Chetty Street, New No. 68, Old No. 299, Bafna Towers, Chennai, TN, IND, 600001
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
57GF Score

Get the complete analysis for NSE:BAFNAPH

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹312.60
Price
₹85.61
GF Value